CAN-3110 Earns FDA Fast Track Designation in Recurrent High-Grade Glioma
Cancer Network | Brain Cancer
by
1w ago
Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma ..read more
Visit website
Bivalent CAR T-Cell Therapy Shows Tumor Shrinkage in Recurrent Glioblastoma
Cancer Network | Brain Cancer
by
1w ago
Findings highlighted tumor reductions in patients with recurrent glioblastoma who received CART-EGFR-IL13Rα2 cells at 2 dose levels ..read more
Visit website
Medical World News® Inside the Practice: CancerNetwork® and Albert H. Kim, MD, PhD, on Treating Brain Tumor Malignancies at the Siteman Cancer Center
Cancer Network | Brain Cancer
by
2M ago
Survival Advantage Demonstrated With Higher-Dose Rhenium-186 Nanoliposome in Recurrent Glioma The FDA has followed the recommendation of its Oncologic Drugs Advisory Committee and issued a complete response letter denying approval to 131I-omburtamab as a treatment for central nervous system and leptomeningeal metastases stemming from neuroblastoma. Radiosurgery and Immunotherapy for Melanoma Patients With Brain Metastases The preliminary safety and efficacy of SONALA-001 is being assessed as part of the SDT-201 study in diffuse intrinsic pontine glioma. FDA Gives Priority Review to Tovorafenib ..read more
Visit website
Clinical Topics
Cancer Network | Brain Cancer
by
2M ago
Treatment Algorithms with the Oncology Brothers ..read more
Visit website
Eflornithine Is Approved by the FDA for High-Risk Neuroblastoma
Cancer Network | Brain Cancer
by
3M ago
Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results from Study 3b and Study ANBL0032 ..read more
Visit website
SONALA-001/Transcranial Ultrasound Device Gets FTD in Pediatric Brain Cancer
Cancer Network | Brain Cancer
by
4M ago
The preliminary safety and efficacy of SONALA-001 is being assessed as part of the SDT-201 study in diffuse intrinsic pontine glioma ..read more
Visit website
FDA Gives Priority Review to Tovorafenib in Pediatric Low-Grade Glioma
Cancer Network | Brain Cancer
by
5M ago
The FDA has set a Prescription Drug User Fee Act date of April 30, 2024 for tovorafenib as a treatment for pediatric patients with relapsed or progressive low-grade glioma ..read more
Visit website
IL4R-Targeting Toxin MDNA55 Yields Promising OS in Recurrent Glioblastoma
Cancer Network | Brain Cancer
by
5M ago
MDNA55 appears tolerable and effective in a cohort of patients enrolled in a phase 2b trial, showing sustained efficacy in subgroup analyses ..read more
Visit website
Olaptesed Pegol Combo Yields ‘Meaningful’ 15-Month Survival in Glioblastoma
Cancer Network | Brain Cancer
by
5M ago
Overall survival is expected to continue improving among patients with glioblastoma being treated with frontline olaptesed pegol plus radiotherapy and bevacizumab who remain on the phase 1/2 GLORA study ..read more
Visit website
ABM-1310 Receives FDA Orphan Drug Designation in BRAF+ Glioblastoma
Cancer Network | Brain Cancer
by
5M ago
Findings from a phase 1 trial highlight the potential tolerability and efficacy of ABM-1310 as a treatment for patients with BRAF-mutated solid tumors ..read more
Visit website

Follow Cancer Network | Brain Cancer on FeedSpot

Continue with Google
Continue with Apple
OR